Indrayani Biotech
7.00
-6.99(-100.00%)
Market Cap₹31.80 Cr
PE Ratio-4.34
IndustryFMCG
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Indrayani Biotech
15Aug 25
Indrayani Biotech Reports Mixed Q1 Results: Standalone Profit Steady, Consolidated Revenue Declines
Indrayani Biotech Limited (IBL) released Q1 financial results showing mixed performance. Standalone net profit slightly increased to ₹12.77 crore, but revenue fell 38% to ₹668.57 crore. Consolidated results were more challenging, with revenue dropping 7.7% to ₹2,910.37 crore and net profit declining 81.6% to ₹15.65 crore. Standalone EPS remained stable at ₹0.03, while consolidated EPS decreased from ₹0.10 to ₹0.03. The company's board meeting was held on August 14, 2025, and statutory auditors provided an unmodified opinion on the results.
 no imag found
Indrayani Biotech
7.00
-6.99
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
LT Foods
384.65
(-0.16%)
KRBL
308.35
(+0.28%)
Kaveri Seed Company
803.00
(-0.97%)
Trualt Bioenergy
394.10
(+1.17%)
GRM Overseas
154.00
(-0.28%)
Sanstar
83.78
(-0.25%)
Gulshan Polyols
155.00
(+0.34%)
Regaal Resources
88.50
(-2.53%)